Pharmaceutical preparations for the treatment of immuno deficiency disorders; intravenous immunoglobulins for use in the treatment of immuno deficiency disorders and in immune replacement therapy; Pharmaceutical preparations for the treatment of dermatomyositis, inflammatory diseases and inflammatory conditions, muscle conditions and skin conditions; pharmaceutical preparations for the treatment of skin rash, weight loss, fever, lung conditions, light sensitivity, calcium deposits, and cardiovascular conditions; pharmaceutical preparations for the treatment of inflammatory myopathy and muscular conditions
Pharmaceutical preparations for the treatment of immuno deficiency disorders; intravenous immunoglobulins for use in the treatment of immuno deficiency disorders and in immune replacement therapy; Pharmaceutical preparations for the treatment of dermatomyositis, inflammatory diseases and inflammatory conditions, muscle conditions and skin conditions; pharmaceutical preparations for the treatment of skin rash, weight loss, fever, lung conditions, light sensitivity, calcium deposits, and cardiovascular conditions; pharmaceutical preparations for the treatment of inflammatory myopathy and muscular conditions; "DM"
Promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals; Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; "IVIG"
Promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals; Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; "IVIG"
Pharmaceutical preparations for the treatment of immunodeficiency disorders; Pharmaceutical preparations for the treatment of chronic inflammatory demyelinating polyneuropathy and primary immunodeficiency; pharmaceutical preparations in the nature of intravenous immunoglobulins for use in the treatment of immunodeficiency disorders and in immune replacement therapy; Surgical and medical apparatus and instruments for subcutaneous treatment, namely, for the administration of subcutaneous therapy; Medical devices for the administration of subcutaneous therapy for use in treating immunodeficiency disorders; Surgical instruments for use in the administration of subcutaneous medicine; medical instruments for use in the administration of subcutaneous infusion of medicine; Medical apparatus and instruments for use in subcutaneous medical procedures; Medical devices for the administration of subcutaneous therapy, namely, medical devices for accessing subcutaneous structures of the human body for the purpose of administering medical treatment
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI; Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI), Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD.
Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events, MACE, in patients within 90 days of an acute myocardial infarction, AMI, with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction, AMI, Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Providing information regarding patient medication reimbursement programs and insurance coverage, namely, insurance reimbursement for immunoglobulin purchases; Administration of a program for financially needy populations for enabling participants to obtain financial assistance in the nature of discounts on goods and/or free product samples; Providing information regarding medical billing support services, namely, medical records coding services for others in the nature of assignment of diagnostic and procedural codes for purposes of reimbursement from insurance; Business administration of patient reimbursement programs; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication; Providing personal support services for patients and families of patients, namely, emotional counseling and emotional support
Educational services, namely, conducting programs and training courses for nurses in the field of blood diseases, illnesses and conditions, as well as, awareness and consequences of immunodeficiency and neurological disorders, the risk of hemolysis occurring in certain patients receiving immunoglobulin infusion therapy and the identification and treatment with intravenous immunoglobulin therapy of patients in whom hemolysis may develop; Educational services, namely, providing online instruction in the field of blood diseases, illnesses and conditions via an online website; Educational services, namely, providing on-line classes, seminars, conferences and workshops in the field of blood conditions, illnesses, and diseases and distribution of training materials in connection therewith; Educational services, namely, developing, arranging, and conducting educational conferences and programs and providing courses of instruction in the field of blood diseases, illnesses and conditions; providing information for patients in the field of education about the stages of diseases, illnesses and medical conditions
Healthcare education services, namely, conducting educational programs for patients, caregivers and/or healthcare professionals concerning immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals; planning and conducting educational conventions and educational meetings related to immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; Printed materials, namely, newsletters, articles and case studies featuring immunoglobulin, immunodeficiency and neurological disorders; Printed publications, namely, brochures, booklets, newsletters, articles, case studies, and teaching materials in the field of immunoglobulin, immunodeficiency and neurological disorders; printed educational materials in the field of immunoglobulin, immunodeficiency and neurological disorders; Healthcare education services, namely, promoting awareness of immunoglobulin, immunodeficiency and neurological disorders, its treatment and its impact on patients, patient families, caregivers and/or healthcare professionals to patients, caregivers and/or healthcare professionals; Providing a website featuring healthcare information in the field of immunoglobulin, immunodeficiency and neurological disorders, and corresponding treatments; Healthcare and healthcare information services, namely, providing information concerning immunoglobulin, immunodeficiency and neurological disorders, their treatment and their impact on patients, patient families, caregivers and/or healthcare professionals; Healthcare and healthcare information services, namely, providing information concerning patient lifestyle and wellness for patients, caregivers, parents, teachers, coaches and friends impacted by immunoglobulin, immunodeficiency and neurological disorders; Providing a website featuring information in the field of the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders; Providing links to the web sites of others featuring information about the diagnosis and treatment of immunoglobulin, immunodeficiency and neurological disorders; "IVIG"
Pharmaceutical preparations and substances for immunoglobulin therapy, the treatment or prevention of primary or secondary immunodeficiencies, autoimmune disease and disorders, blood and/or bleeding disorders and diseases; Pharmaceuticals for the treatment or prevention of blood and/or bleeding disorders; Blood products, namely, blood plasma and blood for medical or therapeutic purposes; Blood products, namely, immunoglobulins for medical and therapeutic purposes; Blood proteins for therapeutic use; Surgical and medical apparatus and instruments for the administration of subcutaneous therapy; Medical devices for the administration of subcutaneous therapy
Pharmaceutical preparations and substances for immunoglobulin therapy, the treatment or prevention of primary or secondary immunodeficiencies, autoimmune disease and disorders, blood and/or bleeding disorders and diseases; Pharmaceuticals for the treatment or prevention of blood and/or bleeding disorders; Blood products, namely, blood plasma and blood for medical or therapeutic purposes, immunoglobulins; Blood proteins for therapeutic use; Surgical and medical apparatus and instruments, namely, for the administration of subcutaneous therapy; Medical devices for the administration of subcutaneous therapy
Educational services in the nature of training courses, seminars, conferences and workshops in the field of health and treatment and distribution of educational materials in connection therewith; Publication of texts and journals regarding the results of clinical trials; Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials; Providing scientific research information in the field of pharmaceuticals and clinical trials; providing information about medical research in the areas of health, pharmaceuticals and clinical trials
Educational services in the nature of training courses, seminars, conferences and workshops in the field of health and treatment and distribution of educational materials in connection therewith; Publication of texts and journals regarding the results of clinical trials; Providing medical information and treatment information in the field of health, pharmaceuticals and clinical trials; Providing scientific research information in the field of pharmaceuticals and clinical trials; providing information about medical research in the areas of health, pharmaceuticals and clinical trials
Providing medical and pharmaceutical information to patients and healthcare practitioners, namely, providing medical information regarding hemolysis and the risk of occurrence in and the treatment of certain patients undergoing human intravenous immunoglobulin therapy and providing information relating to the therapeutic properties of pharmaceuticals for the treatment of hemolysis
Providing medical information regarding immunoglobulin, immunodeficiency and neurological disorders, and treatment of same using immunoglobulin; medical consultations provided to patients requiring letters of medical necessity and patients requiring medical letters for the purpose of appealing denied insurance claims; providing medical information regarding dosing and infusion information for immunoglobulin, immunodeficiency and neurological disorders; providing medical information to patients about the stages of diseases, illnesses and medical conditions
Class 041: [ Education and healthcare educational services, namely, providing training and programs concerning awareness and consequence of hemolysis, the risk of hemolysis occurring in certain patients receiving immunoglobulin infusion therapy and the identification and treatment with intravenous immunoglobulin therapy of patients in whom hemolysis may develop ]; Class 044: Providing medical and pharmaceutical information to patients and healthcare practitioners, namely, providing medical information regarding hemolysis and the risk of occurrence in and the treatment of certain patients undergoing human intravenous immunoglobulin therapy and providing information relating to the therapeutic properties of pharmaceuticals for the treatment of hemolysis
Educational services, namely, providing training for nurses and clinicians on teaching self-administration of subcutaneous immunoglobulin to patients with immune deficiency disorders, for immune replacement therapy, and management of immunoglobulin therapy
Pharmaceutical preparations for the treatment of immuno deficiency disorders; intravenous immunoglobulins for use in the treatment of immuno deficiency disorders and in immune replacement therapy
Class 005: Blood, blood derivatives, pharmaceuticals derived from recombinant DNA Technology all for medical use in the prevention and treatment of blood disorders; intravenous immunoglobulins for use in treatment of immunodeficiency disorders and in immune replacement therapy
Class 005: Pharmaceutical preparations and substances administered for rhesus prophylaxis and for the treatment of human autoimmune disorders; blood products, namely, plasma volume expanders, blood plasma, human albumin, blood clotting factors and immunoglobulins administered for rhesus prophylaxis and for the treatment of human autoimmune disorders; products derived from recombinant DNA technology, namely, plasma volume expanders; human albumin, blood clotting factors and immunoglobulins administered for rhesus prophylaxis and for the treatment of human autoimmune disorders; Class 016: Printed matter and publications, namely books, magazines, newsletters, brochures, leaflets and periodicals, all featuring material in relation to pharmaceutical products, blood, blood products, bleeding disorders, blood fractionations, rhesus prophylaxis and human autoimmune disorders; printed educational and teaching material in the field of pharmaceutical products, blood, blood products, bleeding disorders, blood fractionation, rhesus prophylaxis and human autoimmune disorders; stationery; calendars and posters
